Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ESMO: Pivotal Keytruda Combination Hits And Misses

Executive Summary

Merck & Co’s mega-blockbuster checkpoint inhibitor Keytruda hit new clinical highs and lows at ESMO as the major ramps up efforts to expand the drug’s label by exploring novel combinations and cancer settings.

You may also be interested in...



Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal

Seagen/Astellas announced Phase Ib/II trial data for the combination that could lead to an accelerated approval for the antibody-drug conjugate in first-line bladder cancer.

Keytruda's Urothelial Cancer Claim Goes From Accelerated To Full Approval, With More Limited Scope

US FDA showed some regulatory flexibility by relying on longer-term follow-up from Merck’s original single-arm trial, rather than additional confirmatory studies, to retain the first-line claim, but it narrowed the target population to those with the greatest unmet need; Keytruda indication was one of six 'dangling' accelerated approvals re-examined by Oncologic Drugs Advisory Committee in April.

Janssen’s Spravato Beats Antipsychotic In Depression Trial Designed To Increase Uptake

The controversial nasal spray has improved remission rates over an atypical antipsychotic in patients with a challenging form of depression, in Phase III data which could help boost its uninspiring market performance to date.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147040

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel